Here’s What Hit Delcath Systems (DCTH) in Q3

Core Insights - Riverwater Partners' Micro Opportunities Strategy reported solid absolute returns in Q3 2025 but lagged behind the benchmark due to not keeping pace with the strong market rally [1] - The strategy continues to focus on quality companies amid a volatile environment [1] Company Highlights - Delcath Systems, Inc. (NASDAQ:DCTH) is highlighted as a key stock in the Micro Opportunities Strategy, with a one-month return of 15.14% and a 52-week loss of 16.58% [2] - As of December 15, 2025, Delcath Systems, Inc. closed at $10.08 per share, with a market capitalization of $352.961 million [2] - Delcath Systems, Inc. specializes in liver-directed cancer therapies, utilizing its proprietary Hepzato Kit to deliver high-dose chemotherapy directly to the liver, minimizing systemic exposure [3] - The therapy is currently approved for ocular melanoma with liver metastases, and ongoing trials are exploring its potential in broader indications [3]